Responses

Download PDFPDF
Extended report
Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Running away from your own data

    Dear Editor,

    This is an interesting paper; however I was surprised at the vagueness of the conclusion. The authors showed a significantly increased 'ratio of lymphoma' with adalimumab (4.1) and infliximab (3.6) vs. entanercept (0.9). Unless some confounding variable is discovered, the conclusion would seem clear. Either adalimumab and infliximab predispose to lymphoma, or entanercept prevents it.

    The 'conclusion'...

    Show More
    Conflict of Interest:
    None declared.